Previous Close | 7.09 |
Open | 6.96 |
Bid | 6.95 x 900 |
Ask | 7.00 x 1000 |
Day's Range | 6.80 - 7.14 |
52 Week Range | 1.40 - 30.10 |
Volume | 803,839 |
Avg. Volume | 1,356,664 |
Market Cap | 157.328M |
Beta (5Y Monthly) | 0.30 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.99 |
Earnings Date | Aug 07, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.25 |
DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B.
DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc.Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials.
DURHAM, NC / ACCESSWIRE / January 11, 2021 /Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021.